Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-03-02

AUTHORS

Siew Wan Hee, Adrian Willis, Catrin Tudur Smith, Simon Day, Frank Miller, Jason Madan, Martin Posch, Sarah Zohar, Nigel Stallard

ABSTRACT

BackgroundClinical trials are typically designed using the classical frequentist framework to constrain type I and II error rates. Sample sizes required in such designs typically range from hundreds to thousands of patients which can be challenging for rare diseases. It has been shown that rare disease trials have smaller sample sizes than non-rare disease trials. Indeed some orphan drugs were approved by the European Medicines Agency based on studies with as few as 12 patients. However, some studies supporting marketing authorisation included several hundred patients. In this work, we explore the relationship between disease prevalence and other factors and the size of interventional phase 2 and 3 rare disease trials conducted in the US and/or EU. We downloaded all clinical trials from Aggregate Analysis of ClinialTrials.gov (AACT) and identified rare disease trials by cross-referencing MeSH terms in AACT with the list from Orphadata. We examined the effects of prevalence and phase of study in a multiple linear regression model adjusting for other statistically significant trial characteristics.ResultsOf 186941 ClinicalTrials.gov trials only 1567 (0.8%) studied a single rare condition with prevalence information from Orphadata. There were 19 (1.2%) trials studying disease with prevalence <1/1,000,000, 126 (8.0%) trials with 1–9/1,000,000, 791 (50.5%) trials with 1–9/100,000 and 631 (40.3%) trials with 1–5/10,000. Of the 1567 trials, 1160 (74%) were phase 2 trials. The fitted mean sample size for the rarest disease (prevalence <1/1,000,000) in phase 2 trials was the lowest (mean, 15.7; 95% CI, 8.7–28.1) but were similar across all the other prevalence classes; mean, 26.2 (16.1–42.6), 33.8 (22.1–51.7) and 35.6 (23.3–54.3) for prevalence 1–9/1,000,000, 1–9/100,000 and 1–5/10,000, respectively. Fitted mean size of phase 3 trials of rarer diseases, <1/1,000,000 (19.2, 6.9–53.2) and 1–9/1,000,000 (33.1, 18.6–58.9), were similar to those in phase 2 but were statistically significant lower than the slightly less rare diseases, 1–9/100,000 (75.3, 48.2–117.6) and 1-5/10,000 (77.7, 49.6–121.8), trials.ConclusionsWe found that prevalence was associated with the size of phase 3 trials with trials of rarer diseases noticeably smaller than the less rare diseases trials where phase 3 rarer disease (prevalence <1/100,000) trials were more similar in size to those for phase 2 but were larger than those for phase 2 in the less rare disease (prevalence ≥1/100,000) trials. More... »

PAGES

44

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13023-017-0597-1

DOI

http://dx.doi.org/10.1186/s13023-017-0597-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1084251812

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28253932


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Internet", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prevalence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rare Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sample Size", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Statistics and Epidemiology Unit, Division of Health Sciences, Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK", 
          "id": "http://www.grid.ac/institutes/grid.7372.1", 
          "name": [
            "Statistics and Epidemiology Unit, Division of Health Sciences, Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hee", 
        "givenName": "Siew Wan", 
        "id": "sg:person.01020153570.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01020153570.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Warwick Clinical Trials Unit, Division of Health Sciences, Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK", 
          "id": "http://www.grid.ac/institutes/grid.7372.1", 
          "name": [
            "Warwick Clinical Trials Unit, Division of Health Sciences, Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Willis", 
        "givenName": "Adrian", 
        "id": "sg:person.016044353315.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016044353315.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "North West Hub for Trials Methodology Research, Department of Biostatistics, L69 3GL, Liverpool, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "North West Hub for Trials Methodology Research, Department of Biostatistics, L69 3GL, Liverpool, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tudur Smith", 
        "givenName": "Catrin", 
        "id": "sg:person.01261374732.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261374732.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Trials Consulting and Training Limited, Buckingham, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Clinical Trials Consulting and Training Limited, Buckingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Day", 
        "givenName": "Simon", 
        "id": "sg:person.01135027320.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135027320.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Statistics, Stockholm University, Stockholm, Sweden", 
          "id": "http://www.grid.ac/institutes/grid.10548.38", 
          "name": [
            "Department of Statistics, Stockholm University, Stockholm, Sweden"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miller", 
        "givenName": "Frank", 
        "id": "sg:person.01156632520.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156632520.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Warwick Clinical Trials Unit, Division of Health Sciences, Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK", 
          "id": "http://www.grid.ac/institutes/grid.7372.1", 
          "name": [
            "Warwick Clinical Trials Unit, Division of Health Sciences, Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Madan", 
        "givenName": "Jason", 
        "id": "sg:person.01324150336.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324150336.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Section of Medical Statistics, CeMSIIS, Medical University of Vienna, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Section of Medical Statistics, CeMSIIS, Medical University of Vienna, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Posch", 
        "givenName": "Martin", 
        "id": "sg:person.01322707305.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322707305.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "INSERM, U1138, team 22, Centre de Recherche des Cordeliers, Universit\u00e9 Paris 5, Universit\u00e9 Paris 6, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.417925.c", 
          "name": [
            "INSERM, U1138, team 22, Centre de Recherche des Cordeliers, Universit\u00e9 Paris 5, Universit\u00e9 Paris 6, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zohar", 
        "givenName": "Sarah", 
        "id": "sg:person.01207514343.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207514343.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Statistics and Epidemiology Unit, Division of Health Sciences, Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK", 
          "id": "http://www.grid.ac/institutes/grid.7372.1", 
          "name": [
            "Statistics and Epidemiology Unit, Division of Health Sciences, Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stallard", 
        "givenName": "Nigel", 
        "id": "sg:person.01072460120.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072460120.25"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s13023-016-0464-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045472021", 
          "https://doi.org/10.1186/s13023-016-0464-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13023-014-0170-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032760516", 
          "https://doi.org/10.1186/s13023-014-0170-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1750-1172-9-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042257112", 
          "https://doi.org/10.1186/1750-1172-9-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-90-481-9485-8_2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024495539", 
          "https://doi.org/10.1007/978-90-481-9485-8_2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-03-02", 
    "datePublishedReg": "2017-03-02", 
    "description": "BackgroundClinical trials are typically designed using the classical frequentist framework to constrain type I and II error rates. Sample sizes required in such designs typically range from hundreds to thousands of patients which can be challenging for rare diseases. It has been shown that rare disease trials have smaller sample sizes than non-rare disease trials. Indeed some orphan drugs were approved by the European Medicines Agency based on studies with as few as 12 patients. However, some studies supporting marketing authorisation included several hundred patients. In this work, we explore the relationship between disease prevalence and other factors and the size of interventional phase 2 and 3 rare disease trials conducted in the US and/or EU. We downloaded all clinical trials from Aggregate Analysis of ClinialTrials.gov (AACT) and identified rare disease trials by cross-referencing MeSH terms in AACT with the list from Orphadata. We examined the effects of prevalence and phase of study in a multiple linear regression model adjusting for other statistically significant trial characteristics.ResultsOf 186941 ClinicalTrials.gov trials only 1567 (0.8%) studied a single rare condition with prevalence information from Orphadata. There were 19 (1.2%) trials studying disease with prevalence <1/1,000,000, 126 (8.0%) trials with 1\u20139/1,000,000, 791 (50.5%) trials with 1\u20139/100,000 and 631 (40.3%) trials with 1\u20135/10,000. Of the 1567 trials, 1160 (74%) were phase 2 trials. The fitted mean sample size for the rarest disease (prevalence <1/1,000,000) in phase 2 trials was the lowest (mean, 15.7; 95% CI, 8.7\u201328.1) but were similar across all the other prevalence classes; mean, 26.2 (16.1\u201342.6), 33.8 (22.1\u201351.7) and 35.6 (23.3\u201354.3) for prevalence 1\u20139/1,000,000, 1\u20139/100,000 and 1\u20135/10,000, respectively. Fitted mean size of phase 3 trials of rarer diseases, <1/1,000,000 (19.2, 6.9\u201353.2) and 1\u20139/1,000,000 (33.1, 18.6\u201358.9), were similar to those in phase 2 but were statistically significant lower than the slightly less rare diseases, 1\u20139/100,000 (75.3, 48.2\u2013117.6) and 1-5/10,000 (77.7, 49.6\u2013121.8), trials.ConclusionsWe found that prevalence was associated with the size of phase 3 trials with trials of rarer diseases noticeably smaller than the less rare diseases trials where phase 3 rarer disease (prevalence <1/100,000) trials were more similar in size to those for phase 2 but were larger than those for phase 2 in the less rare disease (prevalence \u22651/100,000) trials.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s13023-017-0597-1", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.3862178", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.3864548", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.6945398", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1036535", 
        "issn": [
          "1750-1172"
        ], 
        "name": "Orphanet Journal of Rare Diseases", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "phase 2 trial", 
      "phase 3 trial", 
      "rare disease trials", 
      "disease trials", 
      "rare disease", 
      "clinical trials", 
      "phase 2", 
      "rarer diseases", 
      "interventional clinical trials", 
      "European Medicines Agency", 
      "thousands of patients", 
      "BackgroundClinical trials", 
      "sample size", 
      "trial characteristics", 
      "rare condition", 
      "mean sample size", 
      "low prevalence", 
      "Medicines Agency", 
      "prevalence 1", 
      "prevalence", 
      "phases of study", 
      "patients", 
      "disease", 
      "MeSH terms", 
      "marketing authorisation", 
      "trials", 
      "small sample size", 
      "disease prevalence", 
      "prevalence information", 
      "linear regression models", 
      "type I", 
      "orphan drugs", 
      "multiple linear regression model", 
      "regression models", 
      "effect of prevalence", 
      "frequentist framework", 
      "analysis of data", 
      "aggregate analysis", 
      "drugs", 
      "study", 
      "ConclusionsWe", 
      "mean size", 
      "AACT", 
      "factors", 
      "analysis", 
      "prevalence classes", 
      "rate", 
      "effect", 
      "size", 
      "authorisation", 
      "data", 
      "list", 
      "relationship", 
      "characteristics", 
      "uses", 
      "information", 
      "conditions", 
      "model", 
      "agencies", 
      "phase", 
      "terms", 
      "class", 
      "hundreds", 
      "design", 
      "thousands", 
      "work", 
      "error rate", 
      "such designs", 
      "EU", 
      "framework"
    ], 
    "name": "Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov", 
    "pagination": "44", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1084251812"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13023-017-0597-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28253932"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13023-017-0597-1", 
      "https://app.dimensions.ai/details/publication/pub.1084251812"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_724.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s13023-017-0597-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13023-017-0597-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13023-017-0597-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13023-017-0597-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13023-017-0597-1'


 

This table displays all metadata directly associated to this object as RDF triples.

248 TRIPLES      21 PREDICATES      105 URIs      93 LITERALS      13 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13023-017-0597-1 schema:about N3f285a8e73a94de18c329f2f3ee30e30
2 N5433ece105cc451ab2c0906500c36323
3 N730773153b094c8fa9a12a226316edc0
4 Nbd4b73a96826427290a52238596c9ea4
5 Ne58f18c22d4d42cf858a3a566007a9f5
6 Nfcb78738cc094a758b87146ce4c05d89
7 anzsrc-for:11
8 anzsrc-for:1117
9 schema:author N89298bc0d7a94b57be8e7cbcd1bfa640
10 schema:citation sg:pub.10.1007/978-90-481-9485-8_2
11 sg:pub.10.1186/1750-1172-9-1
12 sg:pub.10.1186/s13023-014-0170-0
13 sg:pub.10.1186/s13023-016-0464-5
14 schema:datePublished 2017-03-02
15 schema:datePublishedReg 2017-03-02
16 schema:description BackgroundClinical trials are typically designed using the classical frequentist framework to constrain type I and II error rates. Sample sizes required in such designs typically range from hundreds to thousands of patients which can be challenging for rare diseases. It has been shown that rare disease trials have smaller sample sizes than non-rare disease trials. Indeed some orphan drugs were approved by the European Medicines Agency based on studies with as few as 12 patients. However, some studies supporting marketing authorisation included several hundred patients. In this work, we explore the relationship between disease prevalence and other factors and the size of interventional phase 2 and 3 rare disease trials conducted in the US and/or EU. We downloaded all clinical trials from Aggregate Analysis of ClinialTrials.gov (AACT) and identified rare disease trials by cross-referencing MeSH terms in AACT with the list from Orphadata. We examined the effects of prevalence and phase of study in a multiple linear regression model adjusting for other statistically significant trial characteristics.ResultsOf 186941 ClinicalTrials.gov trials only 1567 (0.8%) studied a single rare condition with prevalence information from Orphadata. There were 19 (1.2%) trials studying disease with prevalence <1/1,000,000, 126 (8.0%) trials with 1–9/1,000,000, 791 (50.5%) trials with 1–9/100,000 and 631 (40.3%) trials with 1–5/10,000. Of the 1567 trials, 1160 (74%) were phase 2 trials. The fitted mean sample size for the rarest disease (prevalence <1/1,000,000) in phase 2 trials was the lowest (mean, 15.7; 95% CI, 8.7–28.1) but were similar across all the other prevalence classes; mean, 26.2 (16.1–42.6), 33.8 (22.1–51.7) and 35.6 (23.3–54.3) for prevalence 1–9/1,000,000, 1–9/100,000 and 1–5/10,000, respectively. Fitted mean size of phase 3 trials of rarer diseases, <1/1,000,000 (19.2, 6.9–53.2) and 1–9/1,000,000 (33.1, 18.6–58.9), were similar to those in phase 2 but were statistically significant lower than the slightly less rare diseases, 1–9/100,000 (75.3, 48.2–117.6) and 1-5/10,000 (77.7, 49.6–121.8), trials.ConclusionsWe found that prevalence was associated with the size of phase 3 trials with trials of rarer diseases noticeably smaller than the less rare diseases trials where phase 3 rarer disease (prevalence <1/100,000) trials were more similar in size to those for phase 2 but were larger than those for phase 2 in the less rare disease (prevalence ≥1/100,000) trials.
17 schema:genre article
18 schema:isAccessibleForFree true
19 schema:isPartOf N1deea26a2840493d91677e825241bdb8
20 N5d3c42314ca64fdbab89d3fc5cda94a9
21 sg:journal.1036535
22 schema:keywords AACT
23 BackgroundClinical trials
24 ConclusionsWe
25 EU
26 European Medicines Agency
27 MeSH terms
28 Medicines Agency
29 agencies
30 aggregate analysis
31 analysis
32 analysis of data
33 authorisation
34 characteristics
35 class
36 clinical trials
37 conditions
38 data
39 design
40 disease
41 disease prevalence
42 disease trials
43 drugs
44 effect
45 effect of prevalence
46 error rate
47 factors
48 framework
49 frequentist framework
50 hundreds
51 information
52 interventional clinical trials
53 linear regression models
54 list
55 low prevalence
56 marketing authorisation
57 mean sample size
58 mean size
59 model
60 multiple linear regression model
61 orphan drugs
62 patients
63 phase
64 phase 2
65 phase 2 trial
66 phase 3 trial
67 phases of study
68 prevalence
69 prevalence 1
70 prevalence classes
71 prevalence information
72 rare condition
73 rare disease
74 rare disease trials
75 rarer diseases
76 rate
77 regression models
78 relationship
79 sample size
80 size
81 small sample size
82 study
83 such designs
84 terms
85 thousands
86 thousands of patients
87 trial characteristics
88 trials
89 type I
90 uses
91 work
92 schema:name Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov
93 schema:pagination 44
94 schema:productId N3d8617c3f7894d9cabc833a47b452ee3
95 N66fc673f15da4bcbbbdb841b6c16878d
96 Ne922bf14d86044bfa284b012538bfbc3
97 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084251812
98 https://doi.org/10.1186/s13023-017-0597-1
99 schema:sdDatePublished 2022-09-02T16:00
100 schema:sdLicense https://scigraph.springernature.com/explorer/license/
101 schema:sdPublisher N9b47500ef8f942e89f957904c43d7194
102 schema:url https://doi.org/10.1186/s13023-017-0597-1
103 sgo:license sg:explorer/license/
104 sgo:sdDataset articles
105 rdf:type schema:ScholarlyArticle
106 N1deea26a2840493d91677e825241bdb8 schema:volumeNumber 12
107 rdf:type schema:PublicationVolume
108 N2e391a5791f24ac8954956d7173ac596 rdf:first sg:person.016044353315.27
109 rdf:rest N5e31837cdfc943d4855d68ad1bf4d4f0
110 N3d8617c3f7894d9cabc833a47b452ee3 schema:name doi
111 schema:value 10.1186/s13023-017-0597-1
112 rdf:type schema:PropertyValue
113 N3f285a8e73a94de18c329f2f3ee30e30 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Internet
115 rdf:type schema:DefinedTerm
116 N5433ece105cc451ab2c0906500c36323 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Clinical Trials as Topic
118 rdf:type schema:DefinedTerm
119 N5d3c42314ca64fdbab89d3fc5cda94a9 schema:issueNumber 1
120 rdf:type schema:PublicationIssue
121 N5e31837cdfc943d4855d68ad1bf4d4f0 rdf:first sg:person.01261374732.97
122 rdf:rest Ndbcd0ea62440456a8bfcb10bd7fca128
123 N66fc673f15da4bcbbbdb841b6c16878d schema:name dimensions_id
124 schema:value pub.1084251812
125 rdf:type schema:PropertyValue
126 N730773153b094c8fa9a12a226316edc0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Sample Size
128 rdf:type schema:DefinedTerm
129 N7cc63fd7bfbe4b79b881686426bab503 rdf:first sg:person.01156632520.15
130 rdf:rest Ncdef3c7b3ced404e95ff761f8529be61
131 N890798fc3f0542cba6591997ae5611cb rdf:first sg:person.01322707305.86
132 rdf:rest Ne80bc04976944cf69fd685c35e5afd01
133 N89298bc0d7a94b57be8e7cbcd1bfa640 rdf:first sg:person.01020153570.37
134 rdf:rest N2e391a5791f24ac8954956d7173ac596
135 N9b47500ef8f942e89f957904c43d7194 schema:name Springer Nature - SN SciGraph project
136 rdf:type schema:Organization
137 Nbd4b73a96826427290a52238596c9ea4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Humans
139 rdf:type schema:DefinedTerm
140 Nc1f7e307368a4afa9f61f34188053f9e rdf:first sg:person.01072460120.25
141 rdf:rest rdf:nil
142 Ncdef3c7b3ced404e95ff761f8529be61 rdf:first sg:person.01324150336.10
143 rdf:rest N890798fc3f0542cba6591997ae5611cb
144 Ndbcd0ea62440456a8bfcb10bd7fca128 rdf:first sg:person.01135027320.93
145 rdf:rest N7cc63fd7bfbe4b79b881686426bab503
146 Ne58f18c22d4d42cf858a3a566007a9f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Rare Diseases
148 rdf:type schema:DefinedTerm
149 Ne80bc04976944cf69fd685c35e5afd01 rdf:first sg:person.01207514343.96
150 rdf:rest Nc1f7e307368a4afa9f61f34188053f9e
151 Ne922bf14d86044bfa284b012538bfbc3 schema:name pubmed_id
152 schema:value 28253932
153 rdf:type schema:PropertyValue
154 Nfcb78738cc094a758b87146ce4c05d89 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Prevalence
156 rdf:type schema:DefinedTerm
157 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
158 schema:name Medical and Health Sciences
159 rdf:type schema:DefinedTerm
160 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
161 schema:name Public Health and Health Services
162 rdf:type schema:DefinedTerm
163 sg:grant.3862178 http://pending.schema.org/fundedItem sg:pub.10.1186/s13023-017-0597-1
164 rdf:type schema:MonetaryGrant
165 sg:grant.3864548 http://pending.schema.org/fundedItem sg:pub.10.1186/s13023-017-0597-1
166 rdf:type schema:MonetaryGrant
167 sg:grant.6945398 http://pending.schema.org/fundedItem sg:pub.10.1186/s13023-017-0597-1
168 rdf:type schema:MonetaryGrant
169 sg:journal.1036535 schema:issn 1750-1172
170 schema:name Orphanet Journal of Rare Diseases
171 schema:publisher Springer Nature
172 rdf:type schema:Periodical
173 sg:person.01020153570.37 schema:affiliation grid-institutes:grid.7372.1
174 schema:familyName Hee
175 schema:givenName Siew Wan
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01020153570.37
177 rdf:type schema:Person
178 sg:person.01072460120.25 schema:affiliation grid-institutes:grid.7372.1
179 schema:familyName Stallard
180 schema:givenName Nigel
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072460120.25
182 rdf:type schema:Person
183 sg:person.01135027320.93 schema:affiliation grid-institutes:None
184 schema:familyName Day
185 schema:givenName Simon
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135027320.93
187 rdf:type schema:Person
188 sg:person.01156632520.15 schema:affiliation grid-institutes:grid.10548.38
189 schema:familyName Miller
190 schema:givenName Frank
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156632520.15
192 rdf:type schema:Person
193 sg:person.01207514343.96 schema:affiliation grid-institutes:grid.417925.c
194 schema:familyName Zohar
195 schema:givenName Sarah
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207514343.96
197 rdf:type schema:Person
198 sg:person.01261374732.97 schema:affiliation grid-institutes:None
199 schema:familyName Tudur Smith
200 schema:givenName Catrin
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261374732.97
202 rdf:type schema:Person
203 sg:person.01322707305.86 schema:affiliation grid-institutes:grid.22937.3d
204 schema:familyName Posch
205 schema:givenName Martin
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322707305.86
207 rdf:type schema:Person
208 sg:person.01324150336.10 schema:affiliation grid-institutes:grid.7372.1
209 schema:familyName Madan
210 schema:givenName Jason
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324150336.10
212 rdf:type schema:Person
213 sg:person.016044353315.27 schema:affiliation grid-institutes:grid.7372.1
214 schema:familyName Willis
215 schema:givenName Adrian
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016044353315.27
217 rdf:type schema:Person
218 sg:pub.10.1007/978-90-481-9485-8_2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024495539
219 https://doi.org/10.1007/978-90-481-9485-8_2
220 rdf:type schema:CreativeWork
221 sg:pub.10.1186/1750-1172-9-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042257112
222 https://doi.org/10.1186/1750-1172-9-1
223 rdf:type schema:CreativeWork
224 sg:pub.10.1186/s13023-014-0170-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032760516
225 https://doi.org/10.1186/s13023-014-0170-0
226 rdf:type schema:CreativeWork
227 sg:pub.10.1186/s13023-016-0464-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045472021
228 https://doi.org/10.1186/s13023-016-0464-5
229 rdf:type schema:CreativeWork
230 grid-institutes:None schema:alternateName Clinical Trials Consulting and Training Limited, Buckingham, UK
231 North West Hub for Trials Methodology Research, Department of Biostatistics, L69 3GL, Liverpool, UK
232 schema:name Clinical Trials Consulting and Training Limited, Buckingham, UK
233 North West Hub for Trials Methodology Research, Department of Biostatistics, L69 3GL, Liverpool, UK
234 rdf:type schema:Organization
235 grid-institutes:grid.10548.38 schema:alternateName Department of Statistics, Stockholm University, Stockholm, Sweden
236 schema:name Department of Statistics, Stockholm University, Stockholm, Sweden
237 rdf:type schema:Organization
238 grid-institutes:grid.22937.3d schema:alternateName Section of Medical Statistics, CeMSIIS, Medical University of Vienna, Vienna, Austria
239 schema:name Section of Medical Statistics, CeMSIIS, Medical University of Vienna, Vienna, Austria
240 rdf:type schema:Organization
241 grid-institutes:grid.417925.c schema:alternateName INSERM, U1138, team 22, Centre de Recherche des Cordeliers, Université Paris 5, Université Paris 6, Paris, France
242 schema:name INSERM, U1138, team 22, Centre de Recherche des Cordeliers, Université Paris 5, Université Paris 6, Paris, France
243 rdf:type schema:Organization
244 grid-institutes:grid.7372.1 schema:alternateName Statistics and Epidemiology Unit, Division of Health Sciences, Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK
245 Warwick Clinical Trials Unit, Division of Health Sciences, Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK
246 schema:name Statistics and Epidemiology Unit, Division of Health Sciences, Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK
247 Warwick Clinical Trials Unit, Division of Health Sciences, Warwick Medical School, University of Warwick, CV4 7AL, Coventry, UK
248 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...